An interventional study of POWERbreathe KH2 and Usual Care in Heart Failure, Heart Failure New York Heart Association Class III and Heart Failure New York Heart Association Class IV, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Heart Failure by NYU Langone Health — 3 open to participants now, 3 under way, none of them phase 3. Heart Failure · NYU Langone Health.
Among the 16 studies in Heart Failure by NYU Langone Health, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 with no phase, and was the 16th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →3 of the 16 studies in Heart Failure by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in India
Ages 18+
NYU Langone Health
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 2
First in 1999; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 113 across the 14 interventional studies, 323 across the 2 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
2 of the studies in Heart Failure by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07601828NYU Langone HealthOxygen Delivery Index (ODIN) Study | 2027-05 |
| NCT07862738NYU Langone HealthInspiratory Muscle Training in Hospitalized Patients With Heart Failure Awaiting Advanced Therapies | 2027-05-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Heart Failure by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the feasibility and safety of inspiratory muscle training (IMT) when implemented as part of routine inpatient physical therapy care in patients undergoing evaluation for advanced heart therapies. The secondary aim is to determine if IMT improves 6-minute walk test (6MWT), dyspnea, Maximal Inspiratory Pressure (MIP) pre-operatively. Thirdly, to determine if IMT decreases ICU and hospital length of stay post-operatively.
This randomized prospective, pilot study will enroll 30 adults hospitalized with heart failure and awaiting advanced therapies (LVAD or Heart Transplant). One group will receive usual care PT while the intervention group will be instructed in the use of an inspiratory muscle trainer to be performed at least 5 days a week with the supervision of a physical therapist. Both groups will undergo testing of Maximal Inspiratory Pressure (MIP) using the POWERbreathe® Inspiratory Muscle Trainer. Data collection will include Maximal Inspiratory Pressure (MIP), 6-minute walk test (6MWT) distance, dyspnea at rest and with exertion, at the start, every two weeks from start, and end of study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet institutional criteria for participation in physical therapy and mobility activities prior to enrollment and before each IMT session. Medical stability may include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform IMT 1 set of 30 breaths at 50% MIP, 5 days/week, in addition to usual care physical therapy.
Device: POWERbreathe KH2 · Other: Usual Care
Participants in this arm will receive usual care physical therapy only.
Other: Usual Care
IMT is a noninvasive, exercise-based intervention designed to improve inspiratory muscle strength and endurance by providing a resistive load during inhalation.
Usual care physical therapy may include functional mobility training, therapeutic activities, gait training, and therapeutic exercise, delivered according to the treating physical therapist's clinical judgment and the patient's medical status.
Percentage of completed training session
Time frame: Final Visit (up to 6 months)
Time required to administer and monitor IMT sessions
Time frame: Final Visit (up to 6 months)
Number of left ventricular assist device (LVAD) implantation or heart transplantation
Time frame: Final Visit (up to 6 months)
Change in Six-Minute Walk Test (6MWT) in meters
The 6MWT measures the total distance in meters that a person can walk on a flat, hard surface over a period of 6 minutes to evaluate functional exercise capacity. The primary score is the total distance walked in meters. Healthy adults typically walk between 400 and 700 meters.
Time frame: Baseline, Post-operative
Change in Borg Category-Ratio (CR) 10 Dyspnea Scale at rest
The Borg CR10 Dyspnea Scale is a numerical rating tool that patients use to report how difficult their breathing feels at a specific moment. The scale ranges from 0 (Nothing at all) to 10 (Maximal (the worst breathing difficulty the person has ever experienced)).
Time frame: Baseline, Final Visit (up to 6 months)
Change in Borg CR10 Dyspnea Scale following exertion
The Borg CR10 Dyspnea Scale is a numerical rating tool that patients use to report how difficult their breathing feels at a specific moment. The scale ranges from 0 (Nothing at all) to 10 (Maximal (the worst breathing difficulty the person has ever experienced)).
Time frame: Baseline, Final Visit (up to 6 months)
Change in maximal inspiratory pressure (MIP)
MIP measures the strength of your breathing muscles, like the diaphragm and ribs. MIP values are recorded in centimeters of water (cmH₂O) as negative numbers. Note: Because it measures negative pressure, a larger negative number means stronger muscles
Time frame: Baseline, Final Visit (up to 6 months)
Post-operative ICU length of stay (LOS)
Time frame: From post-operative admission until discharge (up to 4 weeks)
Post-operative hospital LOS
Time frame: From post-operative admission until discharge (up to 4 weeks)
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Angela.stolfi@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access reasonable request. Requests should be directed to Angela.stolfi@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 6 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.